An Extension Study of Methylnaltrexone Bromide (MNTX) in Participants With Advanced Pancreatic Cancer
Status:
Withdrawn
Trial end date:
2024-02-03
Target enrollment:
Participant gender:
Summary
This open-label extension study will evaluate the long-term safety and efficacy of oral MNTX
in participants with advanced pancreatic cancer (adenocarcinoma) who were previously enrolled
in Study SAL-REL-2042 (NCT04083651).